Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by gericon Jul 19, 2013 11:28am

131 Views

Post# 21617982

RE:RE:RE:Q & A with Sarah - July 2013

To make that statement in the NR they have to know the numbers and they're not elaborating. So were the placebo group results the same as the drug group? Will a bowl of porridge every day have the same net effect as RVX-208?

Awhile back I stated that I thought the spinoff was just going to be a self preservation model for management and I still believe that.

Just my opinion.

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023